- Home
- LTH vs SRRK Comparison
LTH vs SRRK Comparison
Compare LTH & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTH | SRRK |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.5B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LTH | SRRK |
|---|---|---|
| Price | $33.09 | $50.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $40.57 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 3.6M | 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.32 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,995,255,000.00 | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $11.45 | $534.24 |
| P/E Ratio | $85.28 | ★ N/A |
| Revenue Growth | ★ 14.28 | N/A |
| 52 Week Low | $24.14 | $27.07 |
| 52 Week High | $35.33 | $52.19 |
Technical Indicators
Market Signals| Indicator | LTH | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 62.12 | 60.54 |
| Support Level | $25.23 | $45.46 |
| Resistance Level | $35.33 | $51.34 |
| Average True Range (ATR) | 1.29 | 2.52 |
| MACD | -0.07 | 0.20 |
| Stochastic Oscillator | 53.14 | 80.31 |
Price Performance
Historical ComparisonAbout LTH Life Time Group Holdings Inc.
Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.